![]() ![]() Phase 1/2 Clinical Trial Design with Intravitreal 4D-150 in Patients with Wet AMD: This Phase 1/2 clinical trial consists of a Dose Exploration stage followed by a randomized Phase 2 stage in which patients will be randomized to one of two doses levels of 4D-150 vs aflibercept in a 2:2:1 ratio (n=50 patients). ![]() ![]() R100 was invented at 4DMT through the Nobel Prize-winning technology, directed evolution (Therapeutic Vector Evolution platform), for intravitreal delivery, penetration through the internal limiting membrane barrier, and efficient transduction and transgene expression within retinal cells in a broad distribution across the entire retina. to discuss the interim clinical data.īackground on 4D-150: The 4D-150 product candidate comprises a dual transgene payload, expressing aflibercept and an anti-VEGF-C RNAi, and the proprietary vector R100 for low dose intravitreal delivery. 4D Molecular Therapeutics will host a conference call on Novemat 8:00 AM E.T. The data focused on safety, tolerability, aflibercept transgene expression and anti-VEGF clinical activity of the 4D-150 genetic medicine in patients enrolled in cohort 1 (n=5 3E10 vg/eye) the data cutoff date was October 13, 2022. announced interim clinical data from cohort 1 of the Phase 1/2 clinical trial of intravitreal 4D-150 for wet AMD. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |